Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
BioPharma Dive
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
pharminent
September 2, 2026 (Last updated: September 3, 2026)
BioPharma Dive
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.